Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.37 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.35 |
| ▸ | GABRD | O14764 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6177967 | 0.85 | HTR3A (0.41) | HTR3AHTR4KCNH2KDM4ESMN1; SMN2 | |
| SCHEMBL5889428 | 0.85 | HTR3A (0.55) | HTR3AHTR4KCNH2KDM4ESMN1; SMN2 | |
| SCHEMBL5777321 | 0.82 | HTR3A (0.43) | HTR3AHTR4KCNH2KDM4ESMN1; SMN2 | |
| SCHEMBL6178061 | 0.82 | KCNH2 (0.41) | HTR3AHTR4KCNH2KDM4ENPC1 | |
| SCHEMBL6178115 | 0.81 | HTR3A (0.42) | HTR3AHTR4KCNH2KDM4ESMN1; SMN2 | |
| SCHEMBL6178995 | 0.78 | DHODH (0.48) | KDM4ESMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL6176173 | 0.76 | HTR3A (0.47) | HTR3AHTR4KCNH2KDM4ESMN1; SMN2 | |
| SCHEMBL5889429 | 0.73 | GABRP (0.38) | HTR3AHTR4KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL5780083 | 0.73 | HTR4 (1.00) | HTR3AHTR4KCNH2 | |
| SCHEMBL6177253 | 0.73 | GRIN2D (0.36) | KDM4ESMN1; SMN2NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012080-B2 | Imidazopyridine compounds as 5-HT4 receptor agonists | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1440071-B1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT 4? RECEPTOR MODULATORS | PFIZER (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6951867-B2 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1543005-A1 | IMIDAZOPYRIDINE COMPUNDS AS 5-HT4 RECEPTOR AGONISTS | PFIZER INC. (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1543004-A1 | N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER INC. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040266814-A1 | Imidazopyridine compounds having 5-HT4 receptor agonistic activity and 5-HT3 receptor antagonistic activity | PFIZER INC | 2004-12-30 | — | — | US | disclosed |
| EP-1440071-A1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT 4? RECEPTOR MODULATORS | Pfizer Japan Inc. (JP) | 2004-07-28 | — | — | EP | disclosed |
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2004-07-01 | — | — | US | disclosed |
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
| WO-2004026869-A1 | IMIDAZOPYRIDINE COMPUNDS AS 5-HT4 RECEPTOR AGONISTS | PFIZER JAPAN INC. (JP) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026868-A1 | N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2004-04-01 | — | — | WO | disclosed |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | UCHIDA CHIKARA (JP) | 2004-02-19 | — | — | US | disclosed |
| US-6624162-B2 | 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. | PFIZER INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003035649-A1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | HTR3A 28/4885HTR4 1/4885KCNH2 962/4885 |
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | HTR3A 35/4885HTR4 1/4885KCNH2 1390/4885 |
| US-20040266814-A1 | Imidazopyridine compounds having 5-HT4 receptor agonistic activity and 5-HT3 receptor antagonistic activity | HTR4, HRH4, GIPR | HTR3A 11/4885HTR4 1/4885KCNH2 1253/4885 |
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | HTR4, GPR4, HRH4 | HTR3A 35/4885HTR4 1/4885KCNH2 840/4885 |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HRH4, HTR4, HRH2 | HTR3A 27/4885HTR4 2/4885KCNH2 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.